Evidence map›Paper›PMID 26026951›Full record

ArticleNeuropharmacology2015

A fluorescent approach for identifying P2X1 ligands.

Marc-David Ruepp, James A Brozik, Iwan J P de Esch, Richard W Farndale, Ruth D Murrell-Lagnado, Andrew J Thompson

Open access · hybridAbstract read
In one paragraph

Article in Neuropharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Marc-David RueppDepartment of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland.
James A BrozikWashington State University, Department of Chemistry, Pullman, WA 99164-4630, USA.
Iwan J P de EschMedicinal Chemistry, VU University Amsterdam, Amsterdam, The Netherlands.
Richard W FarndaleDepartment of Biochemistry, University of Cambridge, Cambridge CB2 1QW, UK.
Ruth D Murrell-LagnadoDepartment of Pharmacology, Tennis Court Road, Cambridge CB2 1PD, UK.
Andrew J ThompsonDepartment of Pharmacology, Tennis Court Road, Cambridge CB2 1PD, UK. Electronic address: ajt44@cam.ac.uk.
Lawn Tennis Association · GBUniversity of Bern · CHUniversity of Cambridge · GBWashington State University · US

Funding

British Heart Foundation PG/13/39/30293British Heart Foundation RG/09/003/27122
6 · The paper itself

Abstract

There are no commercially available, small, receptor-specific P2X1 ligands. There are several synthetic derivatives of the natural agonist ATP and some structurally-complex antagonists including compounds such as PPADS, NTP-ATP, suramin and its derivatives (e.g. NF279, NF449). NF449 is the most potent and selective ligand, but potencies of many others are not particularly high and they can also act at other P2X, P2Y and non-purinergic receptors. While there is clearly scope for further work on P2X1 receptor pharmacology, screening can be difficult owing to rapid receptor desensitisation. To reduce desensitisation substitutions can be made within the N-terminus of the P2X1 receptor, but these could also affect ligand properties. An alternative is the use of fluorescent voltage-sensitive dyes that respond to membrane potential changes resulting from channel opening. Here we utilised this approach in conjunction with fragment-based drug-discovery. Using a single concentration (300 μM) we identified 46 novel leads from a library of 1443 fragments (hit rate = 3.2%). These hits were independently validated by measuring concentration-dependence with the same voltage-sensitive dye, and by visualising the competition of hits with an Alexa-647-ATP fluorophore using confocal microscopy; confocal yielded kon (1.142 × 10(6) M(-1) s(-1)) and koff (0.136 s(-1)) for Alexa-647-ATP (Kd = 119 nM). The identified hit fragments had promising structural diversity. In summary, the measurement of functional responses using voltage-sensitive dyes was flexible and cost-effective because labelled competitors were not needed, effects were independent of a specific binding site, and both agonist and antagonist actions were probed in a single assay. The method is widely applicable and could be applied to all P2X family members, as well as other voltage-gated and ligand-gated ion channels. This article is part of the Special Issue entitled 'Fluorescent Tools in Neuropharmacology'.

Indexed as

FluorescenceAdenosine TriphosphateBenzenesulfonatesBinding SitesCarbocyaninesDose-Response Relationship, DrugGene ExpressionHEK293 CellsHumansLigandsMicroscopy, ConfocalPurinergic P2X Receptor AgonistsPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X1TransfectionVoltage-Sensitive Dye Imaging4,4,',4'',4'''-(carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino)))tetrakis(benzene-1,3-disulfonate)Adenosine TriphosphateAlexa Fluor 647BenzenesulfonatesCarbocyaninesLigandsPurinergic P2X Receptor AgonistsPurinergic P2X Receptor AntagonistsReceptors, Purinergic P2X1Alexa-647FluorescentFragment-based drug discoveryLigand bindingLigand gated ion channelNF449P2X1Pharmacology

Identifiers

PMID26026951
PMCPMC4728187
OpenAlexW414349928

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.